SCHEMBL2374512

SCHEMBL2374512

COC(=O)[C@H](Cc1ccccc1)N(Cc1ccc(N2CCOCC2)nc1)C(=O)/C=C/c1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.46
NOS1 P29475 2/20 0.46
NOS2 P35228 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
STAT3 P40763 1/20 0.42
KDM4E B2RXH2 2/20 0.38
CHRM4 P08173 1/20 0.38
AOC3 Q16853 1/20 0.37
KMT2A Q03164 1/20 0.37
RAF1 P04049 2/20 0.37
BRAF P15056 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
HPGD P15428 1/20 0.36
SOS1 Q07889 1/20 0.36
TGM2 P21980 1/20 0.36
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374516 1.00 NOS3 (0.46) NOS3NOS1NOS2SMN1; SMN2MAPT
SCHEMBL2374519 1.00 NOS3 (0.46) NOS3NOS1NOS2SMN1; SMN2MAPT
SCHEMBL2374679 0.92 KDM4E (0.41) NOS3NOS1NOS2SMN1; SMN2MAPT
SCHEMBL2374683 0.92 KDM4E (0.41) NOS3NOS1NOS2SMN1; SMN2MAPT
SCHEMBL2374687 0.92 KDM4E (0.41) NOS3NOS1NOS2SMN1; SMN2MAPT
SCHEMBL2374376 0.91 KDM4E (0.40) SMN1; SMN2MAPTKDM4EAOC3KMT2A
SCHEMBL2374368 0.91 KDM4E (0.40) SMN1; SMN2MAPTKDM4EAOC3KMT2A
SCHEMBL2374364 0.91 KDM4E (0.40) SMN1; SMN2MAPTKDM4EAOC3KMT2A
SCHEMBL2374944 0.90 TRPM8 (0.42) MAPTKDM4EKMT2A
SCHEMBL2374946 0.90 TRPM8 (0.42) MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 NOS3 783/4885NOS1 996/4885NOS2 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.